EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia

Whitney Hartlage iD, Hannah Imlay iD, Emily S Spivak iD

Antimicrobial Stewardship & Healthcare Epidemiology · 2024 · 4 (1)

DOI: 10.1017/ash.2024.453 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 11.12.2024. Verfasst von Whitney Hartlage und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Veteran's Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A β–lactam plus a macrolide or a respiratory fluoroquinolone alone is recommended as standard empiric antibacterial therapy for non-severe adults hospitalized with community-acquired pneumonia (CAP) per Infectious Diseases Society of America guidelines. However, the evidence in support of adding empiric atypical antibacterial therapy, and specifically the addition of a macrolide, is conflicting and should be balanced with additional factors: the necessity of covering atypical organisms, benefits of macrolide-associated immunomodulation, harms associated with antibiotic use, and selection for antibiotic-resistant organisms. In this review, we examine the role of atypical coverage in standard treatment regimens for patients admitted with non-severe CAP and specifically focus on the addition of macrolides to β–lactams. We conclude that a subset of patients should not be given atypical coverage as part of their regimen.

Autor:innen und Institutionen

  • Division of Infectious Diseases, Veteran's Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
  • Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.

ORCID-Profile: Whitney Hartlage, Hannah Imlay, Emily S Spivak

Zitieren

APA

Hartlage, W., Imlay, H., & Spivak, E. S. (2024). The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology, 4(1). https://doi.org/10.1017/ash.2024.453

Vancouver

Hartlage W, Imlay H, Spivak ES. The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology. 2024;4(1). doi:10.1017/ash.2024.453

BibTeX
@article{Hartlage2024,
  author = {Hartlage, Whitney and Imlay, Hannah and Spivak, Emily S},
  title = {The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia},
  journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
  year = {2024},
  volume = {4},
  number = {1},
  doi = {10.1017/ash.2024.453}
}
Kostenlos starten →